Literature DB >> 25323613

ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation.

Karyn A Goodman, Sarah A Milgrom, Joseph M Herman, May Abdel-Wahab, Nilofer Azad, A William Blackstock, Prajnan Das, Theodore S Hong, Salma K Jabbour, William E Jones, Andre A Konski, Albert C Koong, Rachit Kumar, Miguel Rodriguez-Bigas, William Small, Charles R Thomas, W Warren Suh.   

Abstract

The management of rectal cancer in patients with metastatic disease at presentation is highly variable. There are no phase III trials addressing therapeutic approaches, and the optimal sequencing of chemotherapy, radiation therapy, and surgery remains unresolved. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial. Omitting chemoradiation may not be appropriate in all stage IV patients, particularly those with symptomatic primary tumors. Moreover, outcomes in this setting are vastly different, as some treatments carry the potential for cure in selected patients, while others are purely palliative. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application, by the panel, of a well-established consensus methodology (Modified Delphi) to rate the appropriateness of imaging and treatment procedures. In instances in which evidence is lacking or not definitive, expert opinion may be used as the basis for recommending imaging or treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25323613

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  5 in total

1.  Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma.

Authors:  Emma B Holliday; Andrew Hunt; Y Nancy You; George J Chang; John M Skibber; Miguel A Rodriguez-Bigas; Brian K Bednarski; Cathy Eng; Eugene J Koay; Bruce D Minsky; Cullen Taniguchi; Sunil Krishnan; Joseph M Herman; Prajnan Das
Journal:  J Gastrointest Oncol       Date:  2017-12

2.  A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.

Authors:  Vera Gorbunova; J Thaddeus Beck; Ralf-Dieter Hofheinz; Pilar Garcia-Alfonso; Marina Nechaeva; Antonio Cubillo Gracian; Laszlo Mangel; Elena Elez Fernandez; Dustin A Deming; Ramesh K Ramanathan; Alison H Torres; Danielle Sullivan; Yan Luo; Jordan D Berlin
Journal:  Br J Cancer       Date:  2018-12-11       Impact factor: 7.640

3.  The survival impact of radiotherapy on synchronous metastatic rectal cancer: metastatic site can serve for radiotherapy-decision.

Authors:  Yuan Zhou; Dan Wang; Fengbo Tan; Zhongyi Zhou; Lilan Zhao; Cenap Güngör; Qian Pei; Yuqiang Li; Wenxue Liu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

4.  Comparison of four lymph node staging systems for predicting prognosis for stage IV rectum cancer.

Authors:  Lingyu Han; Shaobo Mo; Wenqiang Xiang; Qingguo Li; Renjie Wang; Ye Xu; Weixing Dai; Guoxiang Cai
Journal:  Ann Transl Med       Date:  2020-02

5.  Effect of alpha-lipoic acid on radiation-induced small intestine injury in mice.

Authors:  Bae Kwon Jeong; Jin Ho Song; Hojin Jeong; Hoon Sik Choi; Jung Hwa Jung; Jong Ryeal Hahm; Seung Hoon Woo; Myeong Hee Jung; Bong-Hoi Choi; Jin Hyun Kim; Ki Mun Kang
Journal:  Oncotarget       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.